I think these ASX blue chips shares are primed for a major rebound in 2026

2025 was not kind to these shares. Here's why things could be better next year.

| More on:
Two men laughing while bouncing on bouncy balls

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL Ltd is well-positioned for a rebound due to its robust presence in global healthcare and ongoing investments, despite recent market anxieties and temporary operational challenges.
  • WiseTech Global's CargoWise platform retains strong growth potential amid recent setbacks; with a recovery in sentiment and successful business adjustments, it could experience a significant upswing.
  • The article highlights opportunities arising from market impatience, encouraging a long-term perspective to capitalise on undervalued high-quality stocks.

Every market cycle produces its winners and losers. And sometimes, the losers aren't poor-quality companies at all, they are simply dealing with temporary headwinds.

That's what makes times like these so interesting. Several high-quality ASX blue chips have been marked down over the past year, not because their businesses are broken, but because the market has lost patience.

For investors who are willing to look beyond the next quarter, that disconnect can create attractive entry points.

Here are two ASX blue chip shares I believe are primed for a major rebound in 2026.

CSL Ltd (ASX: CSL)

CSL has spent decades earning its reputation as one of the highest-quality companies on the ASX. Its plasma therapies, vaccines, and specialty medicines give it a deeply entrenched position in global healthcare, which is a sector where scale, expertise, and regulatory trust matter enormously.

Yet despite this, CSL shares have been hit hard in 2025. Concerns over a margin recovery at CSL Behring, uncertainty surrounding the Seqirus demerger, weak influenza vaccine rates in the United States, and noise around US tariff policy have clouded what remains a fundamentally strong long-term outlook.

Strip out the market anxiety, and the underlying story hasn't changed for this biotech. Plasma collections continue to rise, new therapies are advancing through its R&D pipeline, and CSL is investing heavily in North American manufacturing to support future growth. The company's earnings power and competitive moat remain intact.

It is rare to see CSL trading at such a meaningful discount to its long-term averages. If sentiment improves in 2026, this blue chip ASX share could be one of the ASX's rebound stories.

Wisetech Global Ltd (ASX: WTC)

WiseTech has transformed global logistics software with its flagship CargoWise platform, which is now used by some of the biggest freight forwarders and supply-chain operators on the planet. Its model is sticky, scalable, and increasingly global, which is the kind of combination tech investors dream about.

However, the past year brought a rare step backwards in market sentiment. Founder controversies, delays to product launches, and a shift to its business model have led to a significant share price pullback. But none of these issues reflect a deterioration in the long-term fundamentals.

CargoWise continues to expand its reach through acquisitions, large enterprise customers are deepening their usage, and WiseTech is still growing at a strong rate.

If its performance improves, it stays clear of further controversies, and transitions successfully to its new business model in 2026, I think the rebound could be sharp for this blue chip ASX share.

Motley Fool contributor James Mickleboro has positions in CSL and WiseTech Global. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Three shareholders climbing ladders up into the clouds.
Blue Chip Shares

Are these the best blue-chip ASX shares money can buy?

These are businesses I’d feel comfortable owning regardless of market conditions.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These businesses have appealing qualities...

Read more »

Buy and sell written on a white cube.
52-Week Lows

3 ASX 200 shares worth buying after February's sell-off

February’s sell-off has dragged several ASX 200 growth shares back to more attractive levels.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Blue Chip Shares

Ord Minnett has a 'strongly positive view' on this ASX 200 star

The broker has good things to say about this blue chip.

Read more »

A warehouse worker is standing next to a shelf and using a digital tablet.
Retail Shares

Are Wesfarmers shares a buy for passive income?

The outlook for the blue-chip stock is solid, but far from spectacular.

Read more »

A woman standing on the street looks through binoculars.
Blue Chip Shares

Which ASX shares benefit from a stronger AUD?

Where should investors look with a strengthening AUD?

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Blue Chip Shares

3 fantastic ASX 200 blue chip shares to buy with $5,000

These big-names are highly rated by analysts. But why?

Read more »

A woman looks questioning as she puts a coin into a piggy bank.
Blue Chip Shares

Instead of Westpac shares, I would buy these ASX blue chips

For new money, I’d rather back established businesses with clearer growth runways than rely on the domestic banking cycle.

Read more »